Kleiner Perkins Caufield & Byers

RiverVest finds success in blowing the dust off old compounds

Niall O’Donnell fancies himself an archaeologist of the pharmaceutical persuasion. His firm, RiverVest Ventures, is scoping out the failed and forgotten drugs of big pharma, building companies to repurpose these benched meds for new indications. The aim is to find drugs that have passed for safety in clinical trials, but may have shown limited efficacy […]

presented by
Devices & Diagnostics

Life sciences investment shifting to Europe, Asia

Venture capital investment in the life sciences has fallen 39 percent over the past three years as the costly, lengthy process of getting  approval for pharmaceuticals from the Food and Drug Administration has spurred companies to shift their investments to overseas markets in Europe and Asia. According to the survey of 150 venture capital firms,  […]